Citigroup maintains CRISPR Therapeutics at Buy, raises price target to $90 from $88
Citigroup maintained its Buy rating on CRISPR Therapeutics and increased its price target to $90 from $88, suggesting a 73.8% upside from the Nov 4 close of $51.77. Recent analyst price targets for the company range from $52 to $82.
How this was made

The 30-second read
Why it matters
The price target increase reflects a modest bullish outlook but does not introduce new company fundamentals.
Market read
A small analyst upgrade that may influence short-term trading activity.
What to watch
No new clinical or regulatory news accompanies the upgrade.
Background
Citigroup's analyst note updates its valuation for CRISPR Therapeutics.
Ticker impact
Citigroup raised its price target on CRISPR Therapeutics to $90 from $88.
potential upward pressure as investors price in higher target.
The modest target increase signals confidence but lacks a catalyst, so impact is limited.
Market effects
May slightly boost biotech sector sentiment.
Limited to US biotech investors.
Minimal global effect.
Counterpoint
Target raise could be premature without new data.
Key entities
- analystCitigroup
Equity research firm providing the rating.
- companyCRISPR Therapeutics
Biotech firm developing gene-editing therapies.

